Evaluation of Therapeutic Adherence among Moroccan Hypertensive Patients: About 1482 Cases

Oumaima Naour1*, Rime Benmalek1, Imad Nouamou1, Hatim Zahidi1, El Ghali Benouna1, Rachida Habbal1

1Cardiology department, University Hospital Center Ibn Rochd of Casablanca, Morocco

*Corresponding Author: Oumaima Naour, Resident in cardiology department, University Hospital Center Ibn Rochd of Casablanca, Morocco; Tel: -212-669454602; Email: oumaima.naour@gmail.com

Received Date: 05-06-2020; Accepted Date: 02-07-2020; Published Date: 09-07-2020

Copyright© 2020 by Naour O, et al. All rights reserved under CC BY-NC-ND. This is an open access article distributed under the terms of the Creative Commons Attribution License, which provides freedom to read, share, copy and redistribution of material in any of the medium, provided with the original author and source are credited.

Abstract

Background and Aims: High Blood Pressure (HBP) is a common condition, however, its several complications especially cardiovascular can be associated with significant morbidity and mortality. Hence, the importance of improving its management through patients’ medication, which is a challenge for both the practitioner and the patient.

The aim of our study was to evaluate predictive factors of therapeutic adherence in Moroccan hypertensive outpatients.

Patients and Methods: We conducted a cross-sectional study from September 2015 to June 2019 including hypertensive patients treated in ambulatory cardiology check-ups. Data was collected from a valid questionnaire: Morisky Medication Adherence Scale (MMAS-8).

Results: 1482 patients were included in this study. Good drug adherence was found in 73.6% according to MMAS-8. Poor compliance predictive factors were: lack of social support (p = 0.002), depression (p= 0.017), poor control of hypertension (p <0.0001), insufficient knowledge about the disease (p= 0.031) and some treatment characteristics: daily multiple administration (p = 0.005) and polytherapy (p= 0.005).

Conclusion: Non-compliance to antihypertensive treatment remains a public health issue in Morocco responsible of additional cost for both the patient and society. Hence, the urgent need to put in place effective strategies to limit this phenomenon in our population.
Keywords
High Blood Pressure; Antihypertensive Drugs; Therapeutic Adherence; Moroccan Population

Introduction
High Blood Pressure (HBP) also known as hypertension is a global public health problem. Often called “the silent killer”, it is one of the major causes of premature death worldwide, killing nearly 8 million people every year. Even if HBP represents a common condition, it is a major risk factor for many cardiac, cerebral, vascular and renal diseases. In Morocco, HBP is one of the most frequent reason of consultation in outpatient health services with an overall prevalence of 33.6% in the population over 20 years old and the number keeps on increasing steadily due to progressive population aging and the change of their lifestyle [1]. Antihypertensive medical treatment is the key to treat this pathology, preventing many severe complications and significantly reducing the risk of occurrence of a stroke or ischemic heart disease, which makes the patient’s adherence to his treatment very important [2].

However, among Moroccan population, the number of hypertensive patients with little or no control remains important, which can be explained by poor therapeutic compliance, often because of the patient himself, socio-economic factors or health care system related factors [3].

To date, few studies have evaluated the relationship between adherence to antihypertensive therapy and the occurrence of HBP complications. A better knowledge of this relationship would enable healthcare professionals to identify patients at risk of developing these complications, and would be a first step towards developing interventions to improve compliance to antihypertensive treatment in patients. The aim of this study was to evaluate factors related to therapeutic adherence in Moroccan hypertensive outpatient using the multidimensional adherence model of the World Health Organization (WHO).

Patients and Methods
We conducted a cross-sectional prospective study from September 2015 to June 2019 concerning hypertensive patients treated in ambulatory cardiology consultation at IBN ROCHD university hospital in CASABLANCA, Morocco.

All the patients whose diagnosis of hypertension was confirmed by a cardiologist were included. While were excluded from this study the patients suffering from any important cognitive or psychiatric affection which would prevent the participant from answering the questionnaire.
Therapeutic adherence was measured by the Morisky Medication Adherence Scale (MMAS-8) that contains eight questions. The degree of adhesion was determined by the sum of all correct responses: high compliance (8 points), moderate compliance (6 to <8 points) and poor compliance (<6 points) [4]. In our study, we divided our patients in two groups; group 1: observant patients (high or moderate compliance MMAS-8 ≥6) and group 2: non-observant patients (poor compliance MMAS-8 < 6).

In this study, we studied factors related to:

1) The patient himself: age, sex.

2) The patient’s clinical condition: comorbidities assessed by the Charlson index, depression assessed by the questionnaire "Patient Health Questionnaire" (PHQ9) [5,6].

3) Socio-economic factors: level of education, health insurance and social support measured by the Perceived Social Support Scale [7].

We performed a multivariate analysis using logistic regression in SPSS 21.0. (p<0.05)

As for ethical considerations, the participation in the study was voluntary, consent was free and clear, written or oral. The study was conducted in compliance with the ethical standards of the responsible institution on human subjects as well as with the Helsinki Declaration.

Results

1482 patients treated for HBP were included; mean age of our patients was 59 years +/- 11.2 (33-88 years). The majority of our patients were male with a sex ratio of 1.52; associated cardiovascular risk factors were: diabetes in 42.1%, chronic smoking (27.5%), dyslipidemia (20.6%) and obesity in 18.4% of cases. Moreover, 63.2% of the women included in the study were postmenopausal. The majority of our patients (75.7%) had a comorbidity classified moderate according to the Charlson index.

Regarding the socio-intellectual characteristics of our patients, 1260 (85%) were illiterate and 179 (12.1%) had a stable job with a monthly income.

Concerning the anti-hypertensive therapy: 34% of patients were under monotherapy with a single daily dose and 21.8% took their treatment irregularly. Among our patients, 990 (66.8%) had a controlled hypertension.

The prevalence of medication adherence was 73.6%, however, our patients’ knowledge about their pathology was insufficient, only 39.2% had a satisfactory level of knowledge.

26.4% of our population was considered non-compliant (MMAS-8 < 6). Among them, depression was found in 209 patients (14.1%), no health insurance in 293 patients (19.8%), bad
blood pressure control in 276 patients (18.6%), 313 patients (21.1%) were taking polytherapy with multiple takes during the day.

The different socio-demographic, psychosocial and therapeutic characteristics are showed in Table 1.

A multivariate analysis showed that the predictive factors of poor therapeutic compliance were lack of social support (p= 0.002), depression (p= 0.017), poor control of hypertension (p <0.001), insufficient knowledge about the disease (p= 0.031) and some treatment characteristics such as polytherapy (p = 0.005), multiple intakes (p= 0.005) and skipping a medication intake (p= 0.016) (Table 2).

| Characteristics                                      | Value [n (%)] |
|------------------------------------------------------|---------------|
| Number of Patients                                   | 1482          |
| Patients’ Characteristics                            |               |
| Mean age (years)                                     | 59 +/- 11.2   |
| Sex ratio M:F                                        | 1.52          |
| Stable profession [n (%)]                            | 179 (12.1%)   |
| Education                                            | 221 (14.9%)   |
| Social support                                       | 605 (40.8%)   |
| Co-existing Cardiovascular Risk Factors [n (%)]      |               |
| Diabetes mellitus                                    | 623 (42.1%)   |
| Chronic Smoking                                      | 408 (27.5%)   |
| Hyperlipidemia                                       | 305 (20.6%)   |
| Menopause                                            | 372 (25.1%)   |
| Obesity                                              | 273 (18.4%)   |
| Charlson’s Index for Comorbidities [n (%)]           |               |
| Low                                                  | 138 (9.3%)    |
| Moderate                                             | 1121 (75.7%)  |
| High                                                 | 185 (12.5%)   |
| Very high                                            | 16 (1.1%)     |
| Extremely high                                       | 22 (1.4%)     |
| Antihypertensive Therapy Characteristics [n (%)]     |               |
| Single daily intake                                  | 504 (34.0%)   |
| Monotherapy                                          | 504 (34.0%)   |
| Medication intake skip                               | 474 (22.0%)   |

Table 1: Sociodemographic, psychosocial and therapeutic characteristics of our study population.
|                | Observant Group n (%) | Non-observant Group n (%) | p-value |
|----------------|-----------------------|---------------------------|---------|
| **Gender**     |                       |                           |         |
| Male           | 677 (45.7%)           | 215 (14.5%)               | 0.211   |
| Female         | 413 (27.9%)           | 173 (11.7%)               |         |
| **Stable Profession** | 143 (9.7%)   | 36 (2.4%)                 | 0.275   |
| **Education**  | 138 (9.3%)            | 83 (5.6%)                 | 0.067   |
| **Good Knowledge of Pathology** | 536 (92.4%) | 44 (7.6%)                 | 0.031   |
| **Cardiovascular Risk Factors** |               |                           |         |
| Diabetes Mellitus | 461 (31.1%)       | 161 (10.9%)               | 0.517   |
| Chronic Smoking | 270 (18.2%)         | 94 (6.4%)                 | 0.070   |
| Dyslipidemia    | 209 (14.1%)           | 138 (9.3%)                | 0.227   |
| Menopause       | 213 (14.3%)           | 159 (10.7%)               | 0.413   |
| Obesity         | 163 (10.9%)           | 90 (6.1%)                 | 0.072   |
| **Controlled Hypertension** | 876 (59.2%) | 113 (7.6%)               | <0.0001 |
| **Social Support** | 510 (34.4%)     | 95 (6.4%)                 | 0.001   |
| **Depression**  | 402 (27.1%)           | 209 (14.1%)               | 0.013   |
| **Antihypertensive Therapy Characteristics** |               |                           |         |
| Single Daily Intake | 425 (28.7%)     | 79 (5.3%)                 | 0.004   |
| Monotherapy     | 425 (28.7%)           | 79 (5.3%)                 | 0.004   |
| Medication Intake Skip | 178 (13.4%) | 324 (21.9%)               | 0.016   |

**Table 2:** Predictive factors of hypertensive drug adherence among our study population.

**Discussion**

Evaluating treatment adherence for chronic diseases, such as blood hypertension, is not a simple task. Multiple ways to evaluate drug adherence are available; such as through medical interrogation, medical prescriptions renewal’s control (possibly with the assistance of the pharmacist), the visualization of the cabinets of pharmacy at home, the "pill-count" or count of the remaining tablets, and the use of electronic pill dispensers, and other direct invasive rarely used methods such as blood or urinary drug concentration [8]. Questionnaire evaluation is one of the important methods to estimate drug adherence. It is a simple, effective and commonly used method [9,10].

According to the WHO, there are many factors leading to poor treatment adherence that can be classified into five categories: socio-economic factors, treatment related factors, patient factors and/or those around them, factors associated to the disease and factors related to the health care system [11].
In our study, the prevalence rate of non-adherence to antihypertensive treatment was 73.6%, this rate varies from 30 to 80% depending on the studies [8]. This is the most important cause of uncontrolled hypertension.

In our study, the results did not show a significant influence of age and sex on the level of therapeutic adherence of hypertension; non-compliance concerned all age groups, both men and women, contradicting the data from some studies that have shown that the elderly are not in good health probably for specific reasons such as cognitive impairment and that men are less observant than women [12-14]. The same results of our study were found in Pio et al., study in which age and sex did not appear to be factors of non-adherence to treatment [15].

The level of education and knowledge of our patients about their illness was low; however, there was no statistically significant relationship between education level and poor adherence, unlike what was reported in some studies that confirmed this relationship [14,16,17].

Some psychosocial factors were factors of poor therapeutic compliance in our study, such as depression and lack of social support by family and friends (p = 0.017 and p = 0.002, respectively). Indeed, psychological disorders such as depression form part of the category of non-avoidable factors of non-adherence recognized by the WHO, which was also identified as a predictor of non-adherence in several chronic diseases [8,18,19]. It was also found that family support was an independent factor of good therapeutic compliance [20].

The results of some studies have shown that patients with comorbidities were less observant than others, others found that the presence of diabetes mellitus or dyslipidemia improved adherence [14,21]. Our study did not find a relationship between the level of therapeutic compliance and the presence of comorbidity other than depression.

The constraints related to the cost of treatment also influenced the process of adhesion in several studies [14,22]. This point has not been reached in our series.

In our study a correlation between the therapeutic observance and the HBP control was found, indeed, several studies showed that the non-compliance was associated with a bad control of the arterial blood pressure, and that a bad observance was associated with a higher blood pressure level [23,24]. In a compliance study of hypertensive patients, the level of compliance was higher in patients with statistically significant normalized blood pressure [25].

With respect to treatment-related factors, monotherapy appears to be a factor affecting therapeutic adherence. According to Y Afassinou et al., study, compliance was much worse in patients receiving dual therapy and triple therapy with 56.02% and 69.57% respectively compared to 44.97% patients in monotherapy [15].

According to our results, there is also an association between the multiple treatment regimen during the day and non-adherence, which is similar to the results of some studies that found that the daily intake of the drug influenced the treatment process. For instance, for Y Afassinou et al., 94.12% and 67.39% of their patients who had respectively three or more tablets per day
were poor observers; 76% and 58.16% of those who had three and two doses per day were also bad observers [15]. Konin as well, found 77.3% of patients with more than three tablets per day and 95.3% of those who had three daily intakes to be poor observers [13].

The results of this study supported some, but not all, hypothetical factors; social support, depression, control of hypertension and some aspects of treatment such as the number of daily drug intake, polytherapy, which have been the main obstacle to therapeutic adherence. Thus, the council of adhesion and patients’ education about the disease and its treatment are important for improving the adherence status of patients.

The authors suggest some interventions that have been proven efficient to improve the drug adherence such as a maximum reduction in the number of daily doses of drugs by focusing on monotherapy whenever possible, the patients’ motivation by clearly explaining to them the nature of their disease, the risks and benefits of the treatment adherence through a good physician-patient relationship, as well as the management of psychosocial factors such as depression and social support to improve medication compliance in patients with chronic diseases such as HBP.

Our study is one of the first studies conducted in Morocco evaluating the predictive factors of adherence and compliance to drug therapy in hypertensive patients. The results of this study, need however, to be confirmed on a larger scale.

**Conclusion**

Non-adherence to medical treatment remains a public health problem, particularly in Morocco. Our study shows that there is a lack of therapeutic adherence due to several factors, which can cause many complications with an additional cost for both the patient and society, hence the need to put in place effective strategies to limit this phenomenon in our population.

**References**

1. Ministère de la Santé. (2019). [Last accessed on 30 June, 2020] https://www.sante.gov.ma/Pages/SanteNews.aspx?IDSnews=21
2. Faucon AL, Madjalian AM, Bobrie G, Amar L, Azizi M. Vers de nouvelles cibles de traitement pour l’hypertension artérielle ? Sciences. 2016;32(10):861-6.
3. Berraho M, El Achhab Y, El Rhazi K, Tachfouti N, Benslimane A, Nejjar C. L’hypertension artérielle chez 525 diabétiques de type 2-étude transversale dans trois régions au Maroc. Rev Epidémiologie Santé Publique. 2009;57(S1):15.
4. Tan XI, Patel I, Chang J. Review of the four item Morisky medication adherence scale (MMAS-4) and eight item Morisky medication adherence scale (MMAS-8). Innov Pharm. 2014;5(3):5.
5. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83.

6. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-13.

7. Canty-Mitchell J, Zimet GD. Psychometric properties of the Multidimensional Scale of Perceived Social Support in urban adolescents. Am J Community Psychol. 2000;28(3):391-400.

8. Scheen A, Giet D. Non-observance thérapeutique : causes, conséquences, solutions. Rev Médicale Liège. 2010;65(6):239-45.

9. Lam WY, Fresco P. Medication adherence measures: an overview. BioMed Res Int. 2015;2015.

10. Walsh JC, Mandalia S, Gazzard BG. Responses to a 1-month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome. Aids. 2002;16(2):269-77.

11. Sabaté E, Sabaté E. Adherence to long-term therapies: evidence for action. World Health Organization; 2003.

12. Isaac LM, Tamblyn RM, Team M-CDR. Compliance and cognitive function: A methodological approach to measuring unintentional errors in medication compliance in the elderly. The Gerontologist. 1993;33(6):772-81.

13. Konin C, Adoh M, Coulibaly I, Kramoh E, Safou M, N’guetta R, et al. L’observance thérapeutique et ses facteurs chez l’hypertendu noir africain. Archives des maladies du coeur et des vaisseaux. 2007;100(8):630-4.

14. Essomba NE, Hamadou B, Koum DCK, Atemkeng A, Coppieters Y. Facteurs de Non Observance au Traitement Anti Hypertenseur chez les Adultes à Douala. Health Sci Dis. 2017;18(3).

15. Pio M, Baragou S, Afassinnou Y, Pessinaba S, Atta B, Ehlan K, et al. Adherence to hypertension and its determinants in the cardiology department of the university hospital of lome tokoin. Pan Afr Med J. 2013;14:48.

16. Sharma N, Sharma SK, Maheshwari VD, Sharma KK, Gupta R. Association of low educational status with microvascular complications in type 2 diabetes: Jaipur Diabetes Registry-1. Indian J Endocrinol Metab. 2015;19(5):667.

17. Akpa MR, Agoumou DI, Odia OJ. Drug compliance among hypertensive patients in Port Harcourt, Nigeria. Niger J Med J Natl Assoc Resid Dr Niger. 2005;14(1):55-7.

18. World Health Organization. Adherence to long-term therapies: evidence for action. World Health Organization. 2003.

19. Molloy GJ, Messerli-Bürgy N, Hutton G, Wikman A, Perkins-Porras L, Steptoe A. Intentional and unintentional non-adherence to medications following an acute coronary syndrome: a longitudinal study. J Psychosom Res. 2014;76(5):430-2.

20. Marín-Reyes F, Rodríguez-Morán M. Family support of treatment compliance in essential arterial hypertension. Salud Publica Mex. 2001;43(4):336-9.

21. Perreault S, Lamarre D, Blais L, Dragomir A, Berbiche D, Lalonde L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39(9):1401-8.

22. Ikama MS, Nsitou BM, Loumouamou M, Kimbally-Kaky G, Nkoua JL. L’observance médicamenteuse et ses facteurs dans un groupe d’hypertendus congolais. Pan Afr Med J. 2013;15(1).
23. Gil V, Munoz C, Martinez JL, Belda J, Soriano JE, Merino J. Factors involved in the hypertensive patient non-compliance with treatment. Med Clin (Barc). 1994;102(2):50-3.

24. Girerd X, Radauceanu A, Achard J-M, Fourcade J, Tournier B, Brillet G, et al. Evaluation de l’observance par l’interrogatoire au cours du suivi des hypertendus dans des consultations spécialisées. Arch Mal Cœur Vaiss. 2001;94(8):839-42.

25. Vaur L, Vaisse B, Genes N, Elkik F, Legrand C, Poggi L. Use of electronic pill boxes to assess risk of poor treatment compliance: results of a large-scale trial. Am J Hypertens. 1999;12(4):374-80.